… The first step in manufacturing chimeric antigen receptor (CAR) T cells is to collect autologous
CD3+ lymphocytes by apheresis. Patients, however, often have leukopenia or have other …

… specificity by gene transfer can provide large numbers of tumor-reactive T lymphocytes for
… application of T cells expressing chimeric antigen receptors (CAR). T lymphocytes can be …

… autologous T cells. CARs may be combined with costimulatory ligands, chimeric costimulatory
receptors, or cytokines to further enhance T-cell … Upon their expression in T lymphocytes, …

… autologous T cells … antigen receptor T cells that we infused would result in a clinically evident
antitumor response. Indeed, the infused dose of 1.5×10 5 chimeric antigen receptor T cells …

… -CD19 chimeric antigen receptor (CAR). We assessed the safety and efficacy of administering
autologous anti-CD19 CAR T cells to patients with advanced CD19 + B-cell malignancies. …

… The patient received a conditioning chemotherapy regimen comprising cyclophosphamide
and fludarabine, followed by an infusion of autologous T cells transduced to express an anti-…

… We infused autologous T cells transduced with a CD19-directed chimeric antigen receptor
(… 0.76×10 6 to 20.6×10 6 CTL019 cells per kilogram of body weight. Patients were monitored …

… vector and used to transduce autologous peripheral blood lymphocytes (PBLs) from a patient
… into autologous T cells was 79% CAR + in CD3 + cells and these cells demonstrated high-…

… Transduction of autologous T cells to express CD19-specific chimeric antigen receptors is
a promising immunotherapeutic approach for the treatment of B-cell cancers. We previously …

… As clinical applications for chimeric antigen receptor T cell (CART) therapy extend
beyond … criteria and in vivo characteristics in 158 autologous CART products from 6 single-center …